Based on research from the universities of Bristol and Nottingham, Exonate has now raised $9m to develop a topical eye drop for conditions including diabetic macular edema.
Exonate, a UK-based macular degeneration medication developer based on research from the universities of Bristol and Nottingham, has closed a £1.5m ($1.9m) round backed by University of Bristol’s Enterprise Fund (UBEF) and multi-university venture fund Uniseed, according to Eyewire. Martlet, the corporate angel investment division of aerospace, defence and property group Marshall of Cambridge, also…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
